Biotechnology company developing programmable DNA medicines for precise in vivo cell engineering
Biotechnology company developing programmable DNA medicines for precise in vivo cell engineering. Its platform uses cell-type-specific synthetic promoters and viral or non-viral delivery vehicles, including polymeric and lipid nanoparticles, to express therapeutic payloads in targeted cells. The pipeline targets autoimmune diseases, solid tumors, and genetic disorders.